Bioengineered small extracellular vesicles deliver multiple SARS-CoV-2 antigenic fragments and drive a broad immunological response
© 2024 The Authors. Journal of Extracellular Vesicles published by Wiley Periodicals, LLC on behalf of the International Society for Extracellular Vesicles..
The COVID-19 pandemic highlighted the clear risk that zoonotic viruses pose to global health and economies. The scientific community responded by developing several efficacious vaccines which were expedited by the global need for vaccines. The emergence of SARS-CoV-2 breakthrough infections highlights the need for additional vaccine modalities to provide stronger, long-lived protective immunity. Here we report the design and preclinical testing of small extracellular vesicles (sEVs) as a multi-subunit vaccine. Cell lines were engineered to produce sEVs containing either the SARS-CoV-2 Spike receptor-binding domain, or an antigenic region from SARS-CoV-2 Nucleocapsid, or both in combination, and we tested their ability to evoke immune responses in vitro and in vivo. B cells incubated with bioengineered sEVs were potent activators of antigen-specific T cell clones. Mice immunised with sEVs containing both sRBD and Nucleocapsid antigens generated sRBD-specific IgGs, nucleocapsid-specific IgGs, which neutralised SARS-CoV-2 infection. sEV-based vaccines allow multiple antigens to be delivered simultaneously resulting in potent, broad immunity, and provide a quick, cheap, and reliable method to test vaccine candidates.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Journal of extracellular vesicles - 13(2024), 2 vom: 10. Feb., Seite e12412 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Jackson, Hannah K [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antigen |
|---|
| Anmerkungen: |
Date Completed 14.02.2024 Date Revised 14.02.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.1002/jev2.12412 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM368292584 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM368292584 | ||
| 003 | DE-627 | ||
| 005 | 20240214233332.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240210s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/jev2.12412 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1293.xml |
| 035 | |a (DE-627)NLM368292584 | ||
| 035 | |a (NLM)38339765 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Jackson, Hannah K |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Bioengineered small extracellular vesicles deliver multiple SARS-CoV-2 antigenic fragments and drive a broad immunological response |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.02.2024 | ||
| 500 | |a Date Revised 14.02.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2024 The Authors. Journal of Extracellular Vesicles published by Wiley Periodicals, LLC on behalf of the International Society for Extracellular Vesicles. | ||
| 520 | |a The COVID-19 pandemic highlighted the clear risk that zoonotic viruses pose to global health and economies. The scientific community responded by developing several efficacious vaccines which were expedited by the global need for vaccines. The emergence of SARS-CoV-2 breakthrough infections highlights the need for additional vaccine modalities to provide stronger, long-lived protective immunity. Here we report the design and preclinical testing of small extracellular vesicles (sEVs) as a multi-subunit vaccine. Cell lines were engineered to produce sEVs containing either the SARS-CoV-2 Spike receptor-binding domain, or an antigenic region from SARS-CoV-2 Nucleocapsid, or both in combination, and we tested their ability to evoke immune responses in vitro and in vivo. B cells incubated with bioengineered sEVs were potent activators of antigen-specific T cell clones. Mice immunised with sEVs containing both sRBD and Nucleocapsid antigens generated sRBD-specific IgGs, nucleocapsid-specific IgGs, which neutralised SARS-CoV-2 infection. sEV-based vaccines allow multiple antigens to be delivered simultaneously resulting in potent, broad immunity, and provide a quick, cheap, and reliable method to test vaccine candidates | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a antigen | |
| 650 | 4 | |a extracellular vesicles | |
| 650 | 4 | |a immune presentation | |
| 650 | 4 | |a vaccine | |
| 650 | 7 | |a Vaccines |2 NLM | |
| 700 | 1 | |a Long, Heather M |e verfasserin |4 aut | |
| 700 | 1 | |a Yam-Puc, Juan Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Palmulli, Roberta |e verfasserin |4 aut | |
| 700 | 1 | |a Haigh, Tracey A |e verfasserin |4 aut | |
| 700 | 1 | |a Gerber, Pehuén Pereyra |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, Jin S |e verfasserin |4 aut | |
| 700 | 1 | |a Matheson, Nicholas J |e verfasserin |4 aut | |
| 700 | 1 | |a Young, Lesley |e verfasserin |4 aut | |
| 700 | 1 | |a Trowsdale, John |e verfasserin |4 aut | |
| 700 | 1 | |a Lo, Mathew |e verfasserin |4 aut | |
| 700 | 1 | |a Taylor, Graham S |e verfasserin |4 aut | |
| 700 | 1 | |a Thaventhiran, James E |e verfasserin |4 aut | |
| 700 | 1 | |a Edgar, James R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of extracellular vesicles |d 2012 |g 13(2024), 2 vom: 10. Feb., Seite e12412 |w (DE-627)NLM230631029 |x 2001-3078 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2024 |g number:2 |g day:10 |g month:02 |g pages:e12412 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/jev2.12412 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2024 |e 2 |b 10 |c 02 |h e12412 | ||